A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia
Latest Information Update: 30 Nov 2023
At a glance
- Drugs Gelsolin (Primary)
- Indications COVID-19 pneumonia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors BioAegis Therapeutics
Most Recent Events
- 25 Jan 2023 Status changed from active, no longer recruiting to completed.
- 01 May 2022 According to Eudra record, this trial has been completed in Romania (22 Nov 2021)
- 12 Mar 2021 Planned End Date changed from 1 May 2021 to 1 Jun 2021.